These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 30544079)

  • 21. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
    Puz P; Lasek-Bal A
    Med Sci Monit; 2016 Nov; 22():4277-4282. PubMed ID: 27829656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
    J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
    Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
    Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
    Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
    Fragoso YD
    Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran.
    Ouspid E; Razazian N; Moghadasi AN; Moradian N; Afshari D; Bostani A; Sariaslani P; Ansarian A
    Neurosciences (Riyadh); 2018 Apr; 23(2):129-134. PubMed ID: 29664454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report.
    Baghbanian SM; Amiri MRM
    Neurol Sci; 2021 Mar; 42(3):1175-1177. PubMed ID: 32968870
    [No Abstract]   [Full Text] [Related]  

  • 29. Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
    Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J
    Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute Varicella-Zoster Virus meningitis in a multiple sclerosis patient treated with fingolimod.
    Dimitri D; Pourcher V
    Rev Neurol (Paris); 2022 Apr; 178(4):393-394. PubMed ID: 35000791
    [No Abstract]   [Full Text] [Related]  

  • 33. BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
    Zięba N; Gębka-Kępińska B; Sowa P
    Wiad Lek; 2022; 75(3):735-741. PubMed ID: 35522887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
    Meca-Lallana JE; Oreja-Guevara C; Muñoz D; Olascoaga J; Pato A; Ramió-Torrentà L; Meca-Lallana V; Hernández MA; Marzo ME; Álvarez-Cermeño JC; Rodríguez-Antigüedad A; Montalbán X; Fernández O;
    PLoS One; 2021; 16(10):e0258437. PubMed ID: 34644366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.
    Mitsikostas DD; Orologas A; Dardiotis E; Fakas N; Doskas T; Karageorgiou K; Maltezou M; Iliopoulos I; Vikelis M; Grigoriadis N
    Adv Ther; 2023 May; 40(5):2217-2233. PubMed ID: 36897520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of early disease rebound after fingolimod discontinuation in a patient with multiple sclerosis and SARS-CoV-2 infection.
    Giovannini B; Panelli D; Bianchi F; Siciliano G; Pasquali L
    Neurol Sci; 2024 Jun; 45(6):2423-2426. PubMed ID: 38546935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
    Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
    Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report.
    Petruzzo M; Lanzillo R
    Neurol Sci; 2021 May; 42(Suppl 1):37-39. PubMed ID: 33635428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
    Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
    Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
    Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
    Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.